CSRNP3

Model summary

A nuclear regulatory scaffold that assembles phosphatase-containing complexes to modulate gene expression and cell-fate decisions. By using a cysteine/serine-rich N-terminal module to organize transcriptional co-regulators, it enhances RNA polymerase II–driven transcription at selected loci and couples stress-responsive signaling to apoptotic gene programs. Its nuclear residency enables direct engagement with chromatin and transcription machinery, where phosphatase docking tunes phosphorylation states to coordinate transcriptional activation and pro-apoptotic outputs.

Predicted Gene Ontology terms

1. 01

   I begin with the InterPro architecture.

   The polypeptide is assigned to IPR023260 (Cysteine/serine-rich nuclear protein family) spanning residues 1–583, indicating a full-length member of the CSRNP family. Within this scaffold, an N-terminal module IPR031972 (Cysteine/serine-rich nuclear protein, N-terminal domain) occupies residues 62–279. This ordered layout—an N-terminal CSRNP-specific domain embedded in a larger family-defining framework—implies a modular nuclear regulator rather than an enzyme. The cysteine/serine enrichment and absence of catalytic signatures argue for a regulatory platform that binds other macromolecules. The N-terminal CSRNP domain typically mediates nucleic-acid and chromatin-associated interactions and often nucleates assemblies with signaling enzymes.

2. 02

   From this architecture, the most direct molecular function is non-catalytic complex assembly.

   The CSRNP N-terminal domain provides a binding hub that recruits regulatory partners, consistent with GO:0019902 phosphatase binding. Phosphatase-binding capacity causally links the protein to signal-responsive transcriptional control: docking of serine/threonine phosphatases modulates phosphorylation states of transcription factors and chromatin regulators that the CSRNP scaffold organizes.

3. 03

   This binding-driven mechanism explains two higher-order processes.

   First, by assembling and stabilizing transcriptional co-regulator complexes, the protein enhances gene activation, aligning with GO:0045944 positive regulation of transcription by RNA polymerase II. The CSRNP platform can increase promoter-proximal initiation and elongation by concentrating co-activators and chromatin remodelers at target loci. Second, phosphatase-tuned assemblies can tip cell-fate decisions toward programmed cell death under stress or developmental cues, supporting GO:0043065 positive regulation of apoptotic process. In this view, transcriptional upregulation of pro-apoptotic genes and coordination with phosphatase-controlled checkpoints together drive apoptosis.

4. 04

   Cellular localization follows from the domain identity and function.

   The CSRNP family signature and nuclear-targeting role place the protein in the nucleus, consistent with GO:0005634 nucleus. A nuclear residence is necessary for coupling to chromatin and RNA polymerase II machinery and for integrating apoptotic signaling at the transcriptional level.

5. 05

   Mechanistically, I hypothesize that the N-terminal CSRNP domain nucleates a nuclear hub that binds phosphatases and transcriptional regulators.

   By recruiting PP1/PP2A modules, the complex dephosphorylates transcription factors and chromatin substrates to potentiate RNA polymerase II–dependent transcription at selected loci. Under pro-death signaling, the same assemblies bias output toward apoptotic gene programs. Likely partners include nuclear phosphatases and their adaptors, sequence-specific transcription factors, and chromatin-modifying complexes that together execute transcriptional control and apoptosis coupling.